About Medifocus Inc.

Medifocus, Inc. (TSXV-MFS, OTC-MDFZF.PK) is in the business of development and commercialization of minimally invasive, focused-heat tumor targeted cancer treatment devices and systems. It plans to raise the standards of breast cancer care and treatment by using focused microwave heating to enhance neoadjuvant chemotherapy to provide better tumor shrinkage and control, leading to improved surgical outcomes and ultimately breast preservation.

Medifocus' patented adaptive phased array (APA) microwave focusing technology platform licensed from the Massachusetts Institute of Technology (MIT) provides the design of the Company's unique focused heat treatment systems with the capability to direct precision-focused microwave energy at targeted tumor to induce hyperthermia to shrink or eradicate tumors without undue harm to surrounding tissue.

The Company's goal is to improve outcomes and standards of care in cancer treatment. Its first indication, locally advanced breast cancer (LABC), involves large tumors that are generally treated first with neo-adjuvant chemotherapy to induce tumor shrinkage and then followed by either mastectomy (complete removal of the breast) or lumpectomy (breast conservation surgery), depending on the final size of the tumor. Medifocus' focused-heat treatment can significantly improve the efficacy of neo-adjuvant chemotherapy in shrinking large breast cancer tumors, significantly improving the chance of breast conservation, and decreasing the need for radical breast surgery. Focused microwaves can be used to shrink breast tumors up to 8 cm in diameter, vastly improving the chance of breast conservation for these patients who under normal circumstances will have no option but to undergo mastectomy.

The Company completed a qualifying transaction with Celsion (Canada) Ltd in November 2008 and raised a total of $3 Million as start-up capital. Celsion (Canada) was established from a management buyout from a US listed public company Celsion Corporation. Medifocus owns a proprietary Adaptive Phased Array (APA) microwave focusing technology platform and is developing APA focused heat systems that can target cancerous tumors anywhere in the body with precision controlled heat treatment doses reliably and repeatably.